2021NAVIGATORAnti-TSLP biologicIn 1,061 patients with severe uncontrolled asthma, tezepelumab 210 mg SC every 4 weeks reduced the annualised asthma exacerbation rate compared with placebo.
2018SYGMA 1PRN ICS-formoterolIn 3,849 patients with mild asthma, PRN budesonide-formoterol reduced severe exacerbations compared with PRN terbutaline.
2018SYGMA 2PRN ICS-formoterolIn 4,215 patients with mild asthma, PRN budesonide-formoterol was non-inferior for severe exacerbations compared with daily maintenance budesonide plus PRN terbutaline.
2018LIBERTY ASTHMA QUESTAnti-IL-4Rα biologicIn 1,902 patients with uncontrolled moderate-to-severe asthma, dupilumab 200 or 300 mg every 2 weeks reduced severe exacerbations and improved FEV1 compared with placebo.
2016AUSTRILABA safetyIn 11,679 adolescents and adults with moderate-to-severe asthma, fluticasone-salmeterol was non-inferior for serious asthma-related events compared with fluticasone alone.
2016SIROCCOAnti-IL-5Rα biologicIn 1,205 patients with severe eosinophilic asthma on high-dose ICS/LABA, benralizumab 30 mg every 4 or 8 weeks reduced annual exacerbation rate compared with placebo.
2014MENSAAnti-IL-5 biologicIn 576 patients with severe eosinophilic asthma, subcutaneous mepolizumab 100 mg every 4 weeks reduced exacerbations compared with placebo.
2014SIRIUSOCS sparingIn 135 patients with OCS-dependent severe eosinophilic asthma, mepolizumab 100 mg SC every 4 weeks reduced maintenance oral corticosteroid dose compared with placebo.
2006SMARTLABA safetyIn 26,355 patients with asthma, salmeterol added to usual care increased respiratory-related and asthma-related mortality compared with placebo plus usual care.